Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases when delivered as a combination therapy vs. anti-VEGF-A monotherapies, according to a study.
At the American Society of Retina Specialists meeting, Nathan C. Steinle, MD, of California Retina Consultants said patients who are treated with an anti-VEGF-A inhibitor often have an upregulation of VEGF-C and -D, “and it might represent ... why some of our patients don’t have full or optimal control with anti-VEGF-A alone.”
Previous research demonstrated visual